Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P094 - Evaluation of the Efficacy of Salvage Surgery for Advanced NSCLC Patients After Neoadjuvant (ID 102)
00:00 - 00:00 | Author(s): X. Cao
The clinical effect of gefitinib on patients with EGFR mutational advanced non-small cell lung cancer (NSCLC) was remarkable, but was inevitably impaired by progressive drug resistance, and the median time to progression is about 1 year. When complete resection of residual disease is possible, the patients can then be considered disease free before drug-resistant. We have aggressively performed salvage lobectomy for patients with gefitinib responses and demonstrated down-staging to under ?A stage. The purpose of this study was to evaluate the perioperative safety and survival benefit of the combined treatment.
A total of 19 advanced NSCLC patients undergoing surgery after gefitinib treatment were collected from 2016.06 to 2018.06. Among them, 9 cases were ?B stage, 2 cases were ?C stage and 8 cases were ? stage, according to The 8th Edition UICC Lung Cancer TNM Staging Criteria. All of the 19 patients would make PET/CT scan and assess the clinical stage down-staging to under ?A stage after treating by gefitinib for from 2-6 months. Then all patients were undergoing video-assisted thoracoscopic (VATS) lobectomy and systemic lymph node dissection. Preioperative risk was evaluated and all patients were followed-up regularly.
All patients were successfully performed by VATS lobectomy and the pathologic stage was down-staging to under ?A stage. Of them, 2 patients were 0 stage, 11 patients were ?A stage, 4 patients were ?B stage and 2 patients were ?A stage. The average operative time is ?210